Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Villa

Showing results (551-560 of 566) with videos related to

Pageof 57
Sort By:
Infectious Agents and Cancer|May 6, 2016
Prevalence of human papillomavirus types and variants and p16(INK4a) expression in head and neck squamous cells carcinomas in São Paulo, BrazilJulio C Betiol, Laura Sichero, Henrique O de Olival Costa, et al.
Breast (Edinburgh, Scotland)|December 16, 2020
Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?Andrei Fodor, Chiara Brombin, Paola Mangili, et al.
Urolithiasis|December 13, 2022
Asymptomatic bacteriuria in candidates for active treatment of renal stones: results from an international multicentric study on more than 2600 patientsT Calcagnile, M C Sighinolfi, B Rocco, et al.
British Journal of Cancer|November 23, 2006
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upL L Villa, R L R Costa, C A Petta, et al.
The Lancet. Oncology|May 3, 2005
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialLuisa L Villa, Ronaldo L R Costa, Carlos A Petta, et al.
Annals of the Rheumatic Diseases|March 12, 2005
PRINTO/PRES international website for families of children with rheumatic diseases: www.pediatric-rheumatology.printo.itN Ruperto, P Garcia-Munitis, L Villa, et al.
Vaccine|June 7, 2006
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18Luisa L Villa, Kevin A Ault, Anna R Giuliano, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 1, 2009
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsSusanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, et al.
BMJ (Clinical Research Ed.)|July 22, 2010
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial, Joakim Dillner, Susanne K Kjaer, et al.
Human Vaccines|October 27, 2009
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infectionSven-Eric Olsson, Susanne K Kjaer, Kristján Sigurdsson, et al.
Pageof 57

Showing results (551-560 of 566) with videos related to

Sort By:
Pageof 57
Infectious Agents and Cancer|May 6, 2016
Prevalence of human papillomavirus types and variants and p16(INK4a) expression in head and neck squamous cells carcinomas in São Paulo, BrazilJulio C Betiol, Laura Sichero, Henrique O de Olival Costa, et al.
Breast (Edinburgh, Scotland)|December 16, 2020
Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?Andrei Fodor, Chiara Brombin, Paola Mangili, et al.
Urolithiasis|December 13, 2022
Asymptomatic bacteriuria in candidates for active treatment of renal stones: results from an international multicentric study on more than 2600 patientsT Calcagnile, M C Sighinolfi, B Rocco, et al.
British Journal of Cancer|November 23, 2006
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upL L Villa, R L R Costa, C A Petta, et al.
The Lancet. Oncology|May 3, 2005
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialLuisa L Villa, Ronaldo L R Costa, Carlos A Petta, et al.
Annals of the Rheumatic Diseases|March 12, 2005
PRINTO/PRES international website for families of children with rheumatic diseases: www.pediatric-rheumatology.printo.itN Ruperto, P Garcia-Munitis, L Villa, et al.
Vaccine|June 7, 2006
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18Luisa L Villa, Kevin A Ault, Anna R Giuliano, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 1, 2009
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsSusanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, et al.
BMJ (Clinical Research Ed.)|July 22, 2010
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial, Joakim Dillner, Susanne K Kjaer, et al.
Human Vaccines|October 27, 2009
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infectionSven-Eric Olsson, Susanne K Kjaer, Kristján Sigurdsson, et al.
Pageof 57